Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia

Schizophrenia Research

Volumn 160, Issue 1-3, 2014, Pages 80-87

  Wonodi, Ikwunga ^a   McMahon, Robert P ^a   Krishna, Nithin ^a   Mitchell, Braxton D ^a   Liu, Judy ^a   Glassman, Matthew ^a   Elliot Hong, L ^a   Gold, James M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cognition; Genetic association; KMO; Kynurenine; P50; Schizophrenia

Indexed keywords

KYNURENINE 3 MONOOXYGENASE;

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; ENZYME METABOLISM; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; KMO GENE; MAJOR CLINICAL STUDY; MALE; MICROGLIA; MISSENSE MUTATION; NEUROPSYCHOLOGICAL TEST; P50 GATING; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; ALLELE; EVOKED RESPONSE; GENETICS; GENOTYPING TECHNIQUE; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ALLELES; COGNITION; EVOKED POTENTIALS; FEMALE; GENOTYPING TECHNIQUES; HUMANS; KYNURENINE 3-MONOOXYGENASE; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84928267091     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.10.026     Document Type: Article

References (129)

1. Adler L.E., Pachtman E., Franks R.D., Pecevich M., Waldo M.C., Freedman R. Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol. Psychiatry 1982, 17(6):639-654.
2. Adler L.E., Hoffer L.J., Griffith J., Waldo M.C., Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol. Psychiatry 1992, 32(7):607-616.
3. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K., Flach K., Nagamoto H., Bickford P., Leonard S., Freedman R. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr. Bull. 1998, 24(2):189-202.
4. Alexander K.S., Pocivavsek A., Wu H.Q., Pershing M.L., Schwarcz R., Bruno J.P. Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine. Neuroscience 2013, 238:19-28. 10.1016/j.neuroscience.2013.01.063.
5. Alkondon M., Pereira E.F., Yu P., Arruda E.Z., Almeida L.E., Guidetti P., Fawcett W.P., Sapko M.T., Randall W.R., Schwarcz R., Tagle D.A., Albuquerque E.X. Targeted deletion of the kynurenine aminotransferase ii gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha7 nicotinic receptors in the hippocampus. J. Neurosci. 2004, 24(19):4635-4648.
6. Alkondon M., Pereira E.F., Albuquerque E.X. Endogenous activation of nAChRs and NMDA receptors contributes to the excitability of CA1 stratum radiatum interneurons in rat hippocampal slices: effects of kynurenic acid. Biochem. Pharmacol. 2011, 82(8):842-851.
7. Alkondon M., Pereira E.F., Eisenberg H.M., Kajii Y., Schwarcz R., Albuquerque E.X. Age dependency of inhibition of alpha7 nicotinic receptors and tonically active N-methyl-d-aspartate receptors by endogenously produced kynurenic acid in the brain. J. Pharmacol. Exp. Ther. 2011, 337(3):572-582.
8. Aoyama N., Takahashi N., Saito S., Maeno N., Ishihara R., Ji X., Miura H., Ikeda M., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshita Y., Yoshida K., Iwata N., Inada T., Ozaki N. Association study between kynurenine 3-monooxygenase gene and schizophrenia in the Japanese population. Genes Brain Behav. 2006, 5(4):364-368.
9. Baran H., Jellinger K., Deecke L. Kynurenine metabolism in Alzheimer's disease. J. Neural Transm. 1999, 106(2):165-181.
10. Baran H., Hainfellner J.A., Kepplinger B., Mazal P.R., Schmid H., Budka H. Kynurenic acid metabolism in the brain of HIV-1 infected patients. J. Neural Transm. 2000, 107(10):1127-1138.
11. Baran H., Hainfellner J.A., Kepplinger B. Kynurenic acid metabolism in various types of brain pathology in HIV-1 infected patients. Int. J. Tryptophan. Res. 2012, 5:49-64. 10.4137/IJTR.S10627.
12. Battery, Army Individual Test Manual of Directions and Scoring 1944, War Dept, Adjutant General's Office, Washington, DC.
13. Bayer T.A., Falkai P., Maier W. Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the "two hit hypothesis". J. Psychiatr. Res. 1999, 33(6):543-548.
14. Birch P.J., Grossman C.J., Hayes A.G. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur. J. Pharmacol. 1988, 154(1):85-87.
15. Buffalo E.A., Gillam M.P., Allen R.R., Paule M.G. Acute behavioral effects of MK-801 in rhesus monkeys: assessment using an operant test battery. Pharmacol. Biochem. Behav. 1994, 48(4):935-940.
16. Cannon T.D., van Erp T.G., Bearden C.E., Loewy R., Thompson P., Toga A.W., Huttunen M.O., Keshavan M.S., Seidman L.J., Tsuang M.T. Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions. Schizophr. Bull. 2003, 29(4):653-669.
17. Carpenedo R., Pittaluga A., Cozzi A., Attucci S., Galli A., Raiteri M., Moroni F. Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur. J. Neurosci. 2001, 11:2141-2147.
18. Caspi A., Reichenberg A., Weiser M., Rabinowitz J., Kaplan Z., Knobler H., Davidson-Sagi N., Davidson M. Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophr. Res. 2003, 65(2-3):87-94.
19. Chess A.C., Simoni M.K., Alling T.E., Bucci D.J. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr. Bull. 2007, 33(3):797-804.
20. Chess A.C., Landers A.M., Bucci D.J. l-Kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning. Behav. Brain Res. 2009, 201(2):325-331.
21. Conne B., Stutz A., Vassalli J.D. The 3' untranslated region of messenger RNA: a molecular 'hotspot' for pathology?. Nat. Med. 2000, 6(6):637-641.
22. Consortium, 1000 Genomes Project, and Altshuler D Abecasis GR, Auton A, Brooks LD, Durbin RM, Gibbs RA, Hurles ME, McVean GA. Xue, Yali [added]; Cartwright, Reed A [added]; Altshuler, David; Keebler, Jonathan; Kokko-Gonzales, Paula; Nickerson, Deborah A. 2010. "A map of human genome variation from population-scale sequencing." Nature no. 467(7319):1061-73. doi:10.1038/nature09534. Erratum in: Nature. 2011 May 26;473(7348):544. (467):1061-1073.
23. Consortium, International HapMap The International HapMap Project. Nature 2003, 18(426):789-796.
24. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry 1996, 3(5):241-253.
25. Coyle J.T., Tsai G., Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann. N. Y. Acad. Sci. 2003, 1003:318-327.
26. Cullum C.M., Harris J.G., Waldo M.C., Smernoff E., Madison A., Nagamoto H.T., Griffith J., Adler L.E., Freedman R. Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr. Res. 1993, 10(2):131-141.
27. Dahan O., Gingold H., Pilpel Y. Regulatory mechanisms and networks couple the different phases of gene expression. Trends Genet. 2011, 27(8):316-322. 10.1016/j.tig.2011.05.008.
28. Davis S., Butcher S.P., Morris R.G. The NMDA receptor antagonist D-2-amino-5-phosphonopentanoate (D-AP5) impairs spatial learning and LTP in vivo at intracerebral concentrations comparable to those that block LTP in vitro. J. Neurosci. 1992, 12(1):21-34.
29. Dobelis P., Staley K.J., Cooper D.C. Lack of modulation of nicotinic acetylcholine alpha-7 receptor currents by kynurenic acid in adult hippocampal interneurons. PLoS One 2012, 7(7):e41108. 10.1371/journal.pone.0041108.
30. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., Weinberger D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(12):6917-6922.
31. Erhardt S., Blennow K., Nordin C., Skogh E., Lindström L.H., Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett. 2001, 313(1-2):96-98.
32. Erhardt S., Oberg H., Mathe J.M., Engberg G. Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons. Amino Acids 2001, 20(4):353-362.
33. Erhardt S., Schwieler L., Emanuelsson C., Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol. Psychiatry 2004, 56(4):255-260.
34. Erwin R.J., Turetsky B.I., Moberg P., Gur R.C., Gur R.E. P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophr. Res. 1998, 33(3):157-167.
35. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders 1997, American Psychiatric Publishing, Inc., Arlington, (Reprint, NOT IN FILE).
36. Foster A.C., Kemp J.A., Leeson P.D., Grimwood S., Donald A.E., Marshall G.R., Priestley T., Smith J.D., Carling R.W. Kynurenic acid analogues with improved affinity and selectivity for the glycine site on the N-methyl-d-aspartate receptor from rat brain. Mol. Pharmacol. 1992, 41(5):914-922.
37. Freedman R., Adler L.E., Waldo M.C., Pachtman E., Franks R.D. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol. Psychiatry 1983, 18(5):537-551.
38. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(2):587-592.
39. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., Higgins J., DeFelice M., Lochner A., Faggart M., Liu-Cordero S.N., Rotimi C., Adeyemo A., Cooper R., Ward R., Lander E.S., Daly M.J., Altshuler D. The structure of haplotype blocks in the human genome. Science 2002, 296(5576):2225-2229.
40. Giorgini F., Huang S.Y., Sathyasaikumar K.V., Notarangelo F.M., Thomas M.A., Tararina M., Wu H.Q., Schwarcz R., Muchowski P.J. Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain. J. Biol. Chem. 2013, 288(51):36554-36566. 10.1074/jbc.M113.503813.
41. Gold J.M. Cognitive deficits as treatment targets in schizophrenia. Schizophr. Res. 2004, 72(1):21-28.
42. Gold J.M., Rehkemper G., Binks S.W., Carpenter C.J., Fleming K., Goldberg T.E., Weinberger D.R. Learning and forgetting in schizophrenia. J. Abnorm. Psychol. 2000, 109(3):534-538.
43. Gold J.M., Goldberg R.W., McNary S.W., Dixon L.B., Lehman A.F. Cognitive correlates of job tenure among patients with severe mental illness. Am. J. Psychiatry 2002, 159(8):1395-1402.
44. Goldberg T.E., Gomar J.J. Targeting cognition in schizophrenia research: from etiology to treatment. Am. J. Psychiatry 2009, 166(6):631-634. 10.1176/appi.ajp.2009.09040497.
45. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatr. 1996, 153:321-330.
46. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 2000, 26(1):119-136.
47. Guillemin G.J., Kerr S.J., Smythe G.A., Armati P.J., Brew B.J. Kynurenine pathway metabolism in human astrocytes. Adv. Exp. Med. Biol. 1999, 467:125-131.
48. Hardy G.H. Mendelian proportions in a mixed population. Science 1908, 28:49-50. (Reprinted in Jameson 1977).
49. Harvey P.D., Geyer M.A., Robbins T.W., Krystal J.H. Cognition in schizophrenia: from basic science to clinical treatment. Psychopharmacology (Berl) 2003, 169(3-4):213-214. 10.1007/s00213-003-1581-0.
50. Harvey P.D., Heaton R.K., Carpenter W.T., Green M.F., Gold J.M., Schoenbaum M. Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation. Schizophr. Res. 2012, 140(1-3):1-8. 10.1016/j.schres.2012.03.025.
51. Hill S.K., Reilly J.L., Harris M.S., Rosen C., Marvin R.W., Deleon O., Sweeney J.A. A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia. Schizophr. Res. 2009, 113(2-3):167-175.
52. Hill S.K., Reilly J.L., Keefe R.S., Gold J.M., Bishop J.R., Gershon E.S., Tamminga C.A., Pearlson G.D., Keshavan M.S., Sweeney J.A. Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Am. J. Psychiatry 2013, 170(11):1275-1284. 10.1176/appi.ajp.2013.12101298.
53. Hilmas C., Pereira E.F., Alkondon M., Rassoulpour A., Schwarcz R., Albuquerque E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 2001, 21(19):7463-7473.
54. Hobert O. Gene regulation by transcription factors and microRNAs. Science 2008, 319(5871):1785-1786. 10.1126/science.1151651.
55. Holtze M., Saetre P., Engberg G., Schwieler L., Werge T., Andreassen O.A., Hall H., Terenius L., Agartz I., Jonsson E.G., Schalling M., Erhardt S. Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls. J. Psychiatry Neurosci. 2012, 37(1):53-57.
56. Hong L.E., Summerfelt A., Mitchell B.D., McMahon R.P., Wonodi I., Buchanan R.W., Thaker G.K. Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate. Arch. Gen. Psychiatry 2008, 65(9):1008-1016.
57. Hyman S.E., Fenton W.S. Medicine. What are the right targets for psychopharmacology?. Science 2003, 299(5605):350-351.
58. Insel T.R. Assessing the economic costs of serious mental illness. Am. J. Psychiatry 2008, 165(6):663-665. 10.1176/appi.ajp.2008.08030366.
59. Jaaskelainen E., Juola P., Hirvonen N., McGrath J.J., Saha S., Isohanni M., Veijola J., Miettunen J. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr. Bull. 2013, 39(6):1296-1306. 10.1093/schbul/sbs130.
60. Javitt D.C. Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int. Rev. Neurobiol. 2007, 78:69-108.
61. Johnson G.C., Esposito L., Barratt B.J., Smith A.N., Heward J., Di Genova G., Ueda H., Cordell H.J., Eaves I.A., Dudbridge F., Twells R.C., Payne F., Hughes W., Nutland S., Stevens H., Carr P., Tuomilehto-Wolf E., Tuomilehto J., Gough S.C., Clayton D.G., Todd J.A. Haplotype tagging for the identification of common disease genes. Nat. Genet. 2001, 29(2):233-237. 10.1038/ng1001-233.
62. Kessler R.C., Heeringa S., Lakoma M.D., Petukhova M., Rupp A.E., Schoenbaum M., Wang P.S., Zaslavsky A.M. Individual and societal effects of mental disorders on earnings in the United States: results from the national comorbidity survey replication. Am. J. Psychiatry 2008, 165(6):703-711. 10.1176/appi.ajp.2008.08010126.
63. Kim J.S., Levin E.D. Nicotinic, muscarinic and dopaminergic actions in the ventral hippocampus and the nucleus accumbens: effects on spatial working memory in rats. Brain Res. 1996, 725(2):231-240.
64. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
65. Lahti A.C., Weiler M.A., Tamara Michaelidis B.A., Parwani A., Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001, 25(4):455-467.
66. Lavebratt C., Olsson S., Backlund L., Frisen L., Sellgren C., Priebe L., Nikamo P., Traskman-Bendz L., Cichon S., Vawter M.P., Osby U., Engberg G., Landen M., Erhardt S., Schalling M. The KMO allele encoding Arg(452) is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. Mol. Psychiatry 2014, 19(3):334-341. 10.1038/mp.2013.11.
67. Leonard S., Adams C., Breese C.R., Adler L.E., Bickford P., Byerley W., Coon H., Griffith J.M., Miller C., Myles-Worsley M., Nagamoto H.T., Rollins Y., Stevens K.E., Waldo M., Freedman R. Nicotinic receptor function in schizophrenia. Schizophr. Bull. 1996, 22(3):431-445.
68. Levin E.D., Simon B.B. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology (Berl) 1998, 138(3-4):217-230.
69. Linderholm K.R., Skogh E., Olsson S.K., Dahl M.L., Holtze M., Engberg G., Samuelsson M., Erhardt S. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 2012 May, 38(3):426-432. Epub 2010 Aug 20. 10.1093/schbul/sbq086.
70. Lopes C., Pereira E.F., Wu H.Q., Purushottamachar P., Njar V., Schwarcz R., Albuquerque E.X. Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7* nicotinic receptors. J. Pharmacol. Exp. Ther. 2007, 322(1):48-58.
71. Maher B.J., LoTurco J.J. Disrupted-in-schizophrenia (DISC1) functions presynaptically at glutamatergic synapses. PLoS One 2012, 7(3):e34053. 10.1371/journal.pone.0034053.
72. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996, 14(5):301-307.
73. Martinez-Aran A., Vieta E., Torrent C., Sanchez-Moreno J., Goikolea J.M., Salamero M., Malhi G.S., Gonzalez-Pinto A., Daban C., Alvarez-Grandi S., Fountoulakis K., Kaprinis G., Tabares-Seisdedos R., Ayuso-Mateos J.L. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord. 2007, 9(1-2):103-113. 10.1111/j.1399-5618.2007.00327.x.
74. Martinez-Aran A., Torrent C., Tabares-Seisdedos R., Salamero M., Daban C., Balanza-Martinez V., Sanchez-Moreno J., Manuel Goikolea J., Benabarre A., Colom F., Vieta E. Neurocognitive impairment in bipolar patients with and without history of psychosis. J. Clin. Psychiatry 2008, 69(2):233-239.
75. Maynard T.M., Sikich L., Lieberman J.A., LaMantia A.S. Neural development, cell-cell signaling, and the "two-hit" hypothesis of schizophrenia. Schizophr. Bull. 2001, 27(3):457-476.
76. Millan M.J., Agid Y., Brune M., Bullmore E.T., Carter C.S., Clayton N.S., Connor R., Davis S., Deakin B., DeRubeis R.J., Dubois B., Geyer M.A., Goodwin G.M., Gorwood P., Jay T.M., Joels M., Mansuy I.M., Meyer-Lindenberg A., Murphy D., Rolls E., Saletu B., Spedding M., Sweeney J., Whittington M., Young L.J. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat. Rev. Drug Discov. 2012, 11(2):141-168.
77. Mok M.H., Fricker A.C., Weil A., Kew J.N. Electrophysiological characterisation of the actions of kynurenic acid at ligand-gated ion channels. Neuropharmacology 2009, 57(3):242-249.
78. Montgomery S.B., Dermitzakis E.T. From expression QTLs to personalized transcriptomics. Nat. Rev. Genet. 2011, 12(4):277-282. 10.1038/nrg2969.
79. Moroni F., Russi P., Carla V., Lombardi G. Kynurenic acid is present in the rat brain and its content increases during development and aging processes. Neurosci. Lett. 1988, 94(1-2):145-150.
80. Morris R.G., Anderson E., Lynch G.S., Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-d-aspartate receptor antagonist, AP5. Nature 1986, 319(6056):774-776.
81. Newcomer J.W., Krystal J.H. NMDA receptor regulation of memory and behavior in humans. Hippocampus 2001, 11(5):529-542. 10.1002/hipo.1069.
82. Newcomer J.W., Farber N.B., Jevtovic-Todorovic V., Selke G., Melson A.K., Hershey T., Craft S., Olney J.W. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 1999, 20(2):106-118.
83. Newhouse P.A., Potter A., Levin E.D. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs Aging 1997, 11(3):206-228.
84. Nica A.C., Montgomery S.B., Dimas A.S., Stranger B.E., Beazley C., Barroso I., Dermitzakis E.T. Candidate causal regulatory effects by integration of expression QTLs with complex trait genetic associations. PLoS Genet. 2010, 6(4):e1000895. 10.1371/journal.pgen.1000895.
85. Nilsson L.K., Linderholm K.R., Engberg G., Paulson L., Blennow K., Lindström L.H., Nordin C., Karanti A., Persson P., Erhardt S. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr. Res. 2005, 80(2-3):315-322.
86. Olsson S.K., Samuelsson M., Saetre P., Lindstrom L., Jonsson E.G., Nordin C., Engberg G., Erhardt S., Landen M. Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J. Psychiatry Neurosci. 2010, 35(3):195-199.
87. Olsson S.K., Sellgren C., Engberg G., Landen M., Erhardt S. Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord. 2012, 14(7):719-726. 10.1111/bdi.12009.
88. Parsons C.G., Danysz W., Quack G., Hartmann S., Lorenz B., Wollenburg C., Baran L., Przegalinski E., Kostowski W., Krzascik P., Chizh B., Headley P.M. Novel systemically active antagonists of the glycine site of the N-methyl-d-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J. Pharmacol. Exp. Ther. 1997, 283(3):1264-1275.
89. Perkins M.N., Stone T.W. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 1982, 247(1):184-187.
90. Pocivavsek A., Wu H.Q., Elmer G.I., Bruno J.P., Schwarcz R. Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur. J. Neurosci. 2012, 35(10):1605-1612.
91. Potter D., Summerfelt A., Gold J., Buchanan R.W. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr. Bull. 2006, 32(4):692-700.
92. Potter M.C., Elmer G.I., Bergeron R., Albuquerque E.X., Guidetti P., Wu H.Q., Schwarcz R. Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 2010 Jul, 35(8):1734-1742. Epub 2010 Mar 24. 10.1038/npp.2010.39.
93. Pritchard J.K., Rosenberg N.A. Use of unlinked genetic markers to detect population stratification in association studies. Am. J. Hum. Genet. 1999, 65(1):220-228.
94. Pritchard J.K., Stephens M., Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000, 155(2):945-959.
95. Prouteau A., Verdoux H., Briand C., Lesage A., Lalonde P., Nicole L., Reinharz D., Stip E. Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. Schizophr. Res. 2005, 77(2-3):343-353.
96. Rassoulpour A., Wu H.Q., Ferre S., Schwarcz R. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J. Neurochem. 2005, 93(3):762-765. 10.1111/j.1471-4159.2005.03134.x.
97. Reich D.E., Cargill M., Bolk S., Ireland J., Sabeti P.C., Richter D.J., Lavery T., Kouyoumjian R., Farhadian S.F., Ward R., Lander E.S. Linkage disequilibrium in the human genome. Nature 2001, 411(6834):199-204.
98. Reilly J.L., Frankovich K., Hill S., Gershon E.S., Keefe R.S., Keshavan M.S., Pearlson G.D., Tamminga C.A., Sweeney J.A. Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories. Schizophr. Bull. 2013, 10.1093/schbul/sbt132.
99. Reitan R.M., Wolfson D. The Halstead-Reitan Neuropsychological Test Battery 1971, Neuropsychology Press, Tuscon, AZ.
100. Ripke S., Ripke S., O'Dushlaine C., Chambert K., Moran J.L., Kahler A.K., Akterin S., Bergen S.E., Collins A.L., Crowley J.J., Fromer M., Kim Y., Lee S.H., Magnusson P.K., Sanchez N., Stahl E.A., Williams S., Wray N.R., Xia K., Bettella F., Borglum A.D., Bulik-Sullivan B.K., Cormican P., Craddock N., de Leeuw C., Durmishi N., Gill M., Golimbet V., Hamshere M.L., Holmans P., Hougaard D.M., Kendler K.S., Lin K., Morris D.W., Mors O., Mortensen P.B., Neale B.M., O'Neill F.A., Owen M.J., Milovancevic M.P., Posthuma D., Powell J., Richards A.L., Riley B.P., Ruderfer D., Rujescu D., Sigurdsson E., Silagadze T., Smit A.B., Stefansson H., Steinberg S., Suvisaari J., Tosato S., Verhage M., Walters J.T., Consortium Multicenter Genetic Studies of Schizophrenia, Levinson D.F., Gejman P.V., Kendler K.S., Laurent C., Mowry B.J., O'Donovan M.C., Owen M.J., Pulver A.E., Riley B.P., Schwab S.G., Wildenauer D.B., Dudbridge F., Holmans P., Shi J., Albus M., Alexander M., Campion D., Cohen D., Dikeos D., Duan J., Eichhammer P., Godard S., Hansen M., Lerer F.B., Liang K.Y., Maier W., Mallet J., Nertney D.A., Nestadt G., Norton N., O'Neill F.A., Papadimitriou G.N., Ribble R., Sanders A.R., Silverman J.M., Walsh D., Williams N.M., Wormley B., Consortium Psychosis Endophenotypes International, Arranz M.J., Bakker S., Bender S., Bramon E., Collier D., Crespo-Facorro B., Hall J., Iyegbe C., Jablensky A., Kahn R.S., Kalaydjieva L., Lawrie S., Lewis C.M., Lin K., Linszen D.H., Mata I., McIntosh A., Murray R.M., Ophoff R.A., Powell J., Rujescu D., Van Os J., Walshe M., Weisbrod M., Wiersma D., Consortium Wellcome Trust Case Control, Donnelly P., Barroso I., Blackwell J.M., Bramon E., Brown M.A., Casas J.P., Corvin A.P., Deloukas P., Duncanson A., Jankowski J., Markus H.S., Mathew C.G., Palmer C.N., Plomin R., Rautanen A., Sawcer S.J., Trembath R.C., Viswanathan A.C., Wood N.W., Spencer C.C., Band G., Bellenguez C., Freeman C., Hellenthal G., Giannoulatou E., Pirinen M., Pearson R.D., Strange A., Su Z., Vukcevic D., Donnelly P., Langford C., Hunt S.E., Edkins S., Gwilliam R., Blackburn H., Bumpstead S.J., Dronov S., Gillman M., Gray E., Hammond N., Jayakumar A., McCann O.T., Liddle J., Potter S.C., Ravindrarajah R., Ricketts M., Tashakkori-Ghanbaria A., Waller M.J., Weston P., Widaa S., Whittaker P., Barroso I., Deloukas P., Mathew C.G., Blackwell J.M., Brown M.A., Corvin A.P., McCarthy M.I., Spencer C.C., Bramon E., Corvin A.P., O'Donovan M.C., Stefansson K., Scolnick E., Purcell S., McCarroll S.A., Sklar P., Hultman C.M., Sullivan P.F. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat. Genet. 2013, 45(10):1150-1159. 10.1038/ng.2742.
101. Ross R.G., Olincy A., Harris J.G., Radant A., Adler L.E., Compagnon N., Freedman R. The effects of age on a smooth pursuit tracking task in adults with schizophrenia and normal subjects. Biol. Psychiatry 1999, 46(3):383-391.
102. Rusted J.M., Newhouse P.A., Levin E.D. Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease. Behav. Brain Res. 2000, 113(1-2):121-129.
103. Sanchez-Morla E.M., Santos J.L., Aparicio A., Garcia-Jimenez M.A., Soria C., Arango C. Neuropsychological correlates of P50 sensory gating in patients with schizophrenia. Schizophr. Res. 2013, 143(1):102-106. 10.1016/j.schres.2012.10.017.
104. Sathyasaikumar K.V., Stachowski E.K., Wonodi I., Roberts R.C., Rassoulpour A., McMahon R.P., Schwarcz R. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull 2011, 37(6):1147-1156.
105. Scharfman H.E., Goodman J.H., Schwarcz R. Electrophysiological effects of exogenous and endogenous kynurenic acid in the rat brain: studies in vivo and in vitro. Amino Acids 2000, 19(1):283-297.
106. Schizophrenia Psychiatric Genome-Wide Association Study, Consortium Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 2011, 43(10):969-976. 10.1038/ng.940.
107. Schwarcz R., Whetsell W.O., Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983, 219(4582):316-318.
108. Schwarcz R., Rassoulpour A., Wu H.Q., Medoff D., Tamminga C.A., Roberts R.C. Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 2001, 50(7):521-530.
109. Sheffield J.M., Gold J.M., Strauss M.E., Carter C.S., Macdonald A.W., Ragland J.D., Silverstein S.M., Barch D.M. Common and specific cognitive deficits in schizophrenia: relationships to function. Cogn. Affect. Behav. Neurosci. 2013, 10.3758/s13415-013-0211-5.
110. Shepard P.D., Joy B., Clerkin L., Schwarcz R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 2003, 28(8):1454-1462.
111. Smith A.K., Edgar J.C., Huang M., Lu B.Y., Thoma R.J., Hanlon F.M., McHaffie G., Jones A.P., Paz R.D., Miller G.A., Canive J.M. Cognitive abilities and 50- and 100-msec paired-click processes in schizophrenia. Am. J. Psychiatry 2010, 167(10):1264-1275. 10.1176/appi.ajp.2010.09071059.
112. Soni A. The Five Most Costly Conditions, 1996 and 2006: Estimates for the U.S. Civilian Noninstitutionalized Population. Statistical Brief #248 July 2009, Agency for Healthcare Research and Quality, Rockville, MD, http://www.meps.ahrq.gov/mepsweb/data_files/publications/st248/stat248.pdf.
113. Stahl S.M. The genetics of schizophrenia converge upon the NMDA glutamate receptor. CNS Spectr. 2007, 12(8):583-588.
114. Stone T.W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 1993, 45(3):309-379.
115. Stone T.W., Darlington L.G. The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. Br. J. Pharmacol. 2013, 169(6):1211-1227. 10.1111/bph.12230.
116. Stone T.W., Perkins M.N. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol. 1981, 72(4):411-412.
117. Stone T.W., Stoy N., Darlington L.G. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol. Sci. 2013, 34(2):136-143. 10.1016/j.tips.2012.09.006.
118. Tamminga C.A. The neurobiology of cognition in schizophrenia. J. Clin. Psychiatry 2006, 67(9):e11.
119. Thaker G.K., Wonodi I., Avila M.T., Hong L.E., Stine O.C. Catechol O-methyltransferase polymorphism and eye tracking in schizophrenia: a preliminary report. Am. J. Psychiatry 2004, 161(12):2320-2322.
120. Thoma R.J., Hanlon F.M., Moses S.N., Edgar J.C., Huang M., Weisend M.P., Irwin J., Sherwood A., Paulson K., Bustillo J., Adler L.E., Miller G.A., Canive J.M. Lateralization of auditory sensory gating and neuropsychological dysfunction in schizophrenia. Am. J. Psychiatry 2003, 160(9):1595-1605.
121. Wang G., Zhu J.J. DISC1 dynamically regulates synaptic N-methyl-d-aspartate responses in excitatory neurons. Biol. Psychiatry 2014, 75(5):348-350. 10.1016/j.biopsych.2013.12.003.
122. Warrington E.K. Recognition Memory Test manual 1984, NFER-Nelson, UK.
123. Wechsler D. Manual for the Wechsler Adult Intelligence Scale 1997, The Psychological Corporation, San Antonio, Texas, (Reprint, NOT IN FILE). Third edition.
124. Wechsler D. Wechsler Abbreviated Scale of Intelligence. WASI 1999, Psychological Group, San Antonio.
125. Wei J., Graziane N.M., Wang H., Zhong P., Wang Q., Liu W., Hayashi-Takagi A., Korth C., Sawa A., Brandon N.J., Yan Z. Regulation of N-methyl-d-aspartate receptors by disrupted-in-schizophrenia-1. Biol. Psychiatry 2014, 75(5):414-424. 10.1016/j.biopsych.2013.06.009.
126. Wolf H. Studies on tryptophan metabolism in man. Scand. J. Clin. Lab. Invest. 1974, 136S:1-186.
127. Wonodi I., Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr. Bull. 2010, 36(2):211-218.
128. Wonodi I., Hong L.E., Stine O.C., Mitchell B.D., Elliott A., Roberts R.C., Conley R.R., McMahon R.P., Thaker G.K. Dopamine transporter polymorphism modulates oculomotor function and DAT1 mRNA expression in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2009, 150B(2):282-289.
129. Wonodi I., Stine O.C., Sathyasaikumar K.V., Roberts R.C., Mitchell B.D., Hong L.E., Kajii Y., Thaker G.K. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch. Gen. Psychiatry 2011, 68(7):665-674.